Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.

Hdl Handle:
http://hdl.handle.net/10147/620598
Title:
Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
Authors:
McEvoy, Lynda M; O'Toole, Sharon A; Spillane, Cathy D; Martin, Cara M; Gallagher, Michael F; Stordal, Britta; Blackshields, Gordon; Sheils, Orla; O'Leary, John J
Citation:
Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer. 2015, 15:547 BMC Cancer
Publisher:
Springer
Journal:
BMC cancer
Issue Date:
2015
URI:
http://hdl.handle.net/10147/620598
DOI:
10.1186/s12885-015-1539-8
PubMed ID:
26205780
Additional Links:
http://bmccancer.biomedcentral.com/articles/10.1186/s12885-015-1539-8
Abstract:
Ovarian cancer is associated with poor long-term survival due to late diagnosis and development of chemoresistance. Tumour hypoxia is associated with many features of tumour aggressiveness including increased cellular proliferation, inhibition of apoptosis, increased invasion and metastasis, and chemoresistance, mostly mediated through hypoxia-inducible factor (HIF)-1α. While HIF-1α has been associated with platinum resistance in a variety of cancers, including ovarian, relatively little is known about the importance of the duration of hypoxia. Similarly, the gene pathways activated in ovarian cancer which cause chemoresistance as a result of hypoxia are poorly understood. This study aimed to firstly investigate the effect of hypoxia duration on resistance to cisplatin in an ovarian cancer chemoresistance cell line model and to identify genes whose expression was associated with hypoxia-induced chemoresistance.
Item Type:
Article
Language:
en
Keywords:
CANCER, OVARIAN
MeSH:
Angiopoietins; Antineoplastic Agents; Biomarkers, Tumor; Cell Hypoxia; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Ovarian Neoplasms; Receptor, ErbB-3
ISSN:
1471-2407

Full metadata record

DC FieldValue Language
dc.contributor.authorMcEvoy, Lynda Men
dc.contributor.authorO'Toole, Sharon Aen
dc.contributor.authorSpillane, Cathy Den
dc.contributor.authorMartin, Cara Men
dc.contributor.authorGallagher, Michael Fen
dc.contributor.authorStordal, Brittaen
dc.contributor.authorBlackshields, Gordonen
dc.contributor.authorSheils, Orlaen
dc.contributor.authorO'Leary, John Jen
dc.date.accessioned2016-09-20T11:26:42Z-
dc.date.available2016-09-20T11:26:42Z-
dc.date.issued2015-
dc.identifier.citationIdentifying novel hypoxia-associated markers of chemoresistance in ovarian cancer. 2015, 15:547 BMC Canceren
dc.identifier.issn1471-2407-
dc.identifier.pmid26205780-
dc.identifier.doi10.1186/s12885-015-1539-8-
dc.identifier.urihttp://hdl.handle.net/10147/620598-
dc.description.abstractOvarian cancer is associated with poor long-term survival due to late diagnosis and development of chemoresistance. Tumour hypoxia is associated with many features of tumour aggressiveness including increased cellular proliferation, inhibition of apoptosis, increased invasion and metastasis, and chemoresistance, mostly mediated through hypoxia-inducible factor (HIF)-1α. While HIF-1α has been associated with platinum resistance in a variety of cancers, including ovarian, relatively little is known about the importance of the duration of hypoxia. Similarly, the gene pathways activated in ovarian cancer which cause chemoresistance as a result of hypoxia are poorly understood. This study aimed to firstly investigate the effect of hypoxia duration on resistance to cisplatin in an ovarian cancer chemoresistance cell line model and to identify genes whose expression was associated with hypoxia-induced chemoresistance.en
dc.language.isoenen
dc.publisherSpringeren
dc.relation.urlhttp://bmccancer.biomedcentral.com/articles/10.1186/s12885-015-1539-8en
dc.rightsArchived with thanks to BMC canceren
dc.subjectCANCER, OVARIANen
dc.subject.meshAngiopoietins-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshBiomarkers, Tumor-
dc.subject.meshCell Hypoxia-
dc.subject.meshCell Line, Tumor-
dc.subject.meshCisplatin-
dc.subject.meshDrug Resistance, Neoplasm-
dc.subject.meshFemale-
dc.subject.meshGene Expression Regulation, Neoplastic-
dc.subject.meshHumans-
dc.subject.meshHypoxia-Inducible Factor 1, alpha Subunit-
dc.subject.meshOvarian Neoplasms-
dc.subject.meshReceptor, ErbB-3-
dc.titleIdentifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.en
dc.typeArticleen
dc.identifier.journalBMC canceren
dc.description.fundingOtheren
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.